Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials.
10.3346/jkms.2015.30.10.1453
- Author:
Jinkyeong PARK
1
;
Jung Su LEE
;
Chinkook RHEE
;
Yeon Mok OH
Author Information
1. Department of Critical Care, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Meta-Analysis
- Keywords:
Pulmonary Disease, Chronic Obstructive;
Indacaterol;
Procaterol;
Cough;
Phlegm;
Dyspnea
- MeSH:
Administration, Inhalation;
Anti-Bacterial Agents/therapeutic use;
Bronchodilator Agents/*therapeutic use;
Cough/*drug therapy;
Dyspnea/*drug therapy;
Forced Expiratory Volume/drug effects;
Humans;
Indans/*therapeutic use;
Placebos/administration & dosage;
Pulmonary Disease, Chronic Obstructive/*drug therapy;
Quinolones/*therapeutic use;
Sputum/*drug effects;
Surveys and Questionnaires;
Treatment Outcome
- From:Journal of Korean Medical Science
2015;30(10):1453-1458
- CountryRepublic of Korea
- Language:English
-
Abstract:
We investigated the effects of indacaterol on cough and phlegm in patients with stable chronic obstructive pulmonary disease (COPD). We performed a meta-analysis with five randomized controlled trials (RCTs) of indacaterol in stable COPD patients. The symptom severity was defined using the St. George's Respiratory Questionnaire (SGRQ). We analyzed patients treated with 150 microg (n = 945) and 300 microg (n = 832) out of 3,325 patients who completed the SGRQ from five RCTs. After a 12-week treatment of 150 microg indacaterol, cough improvement was reported in 36.5% (316/866) of patients treated with indacaterol vs. 32.2% (259/804) patients treated with placebo (Relative Ratio [RR], 1.13; 95% confidence interval [CI], 0.99-1.29). Phlegm improvement was reported in 31.0% (247/798) of patients treated with indacaterol vs. 30.6% (225/736) of patients treated with placebo (RR, 1.01; 95% CI, 0.87-1.18). Dyspnea improvement was reported in 39.5% (324/820) of patients treated with indacaterol vs. 31.5% (237/753) patients treated with placebo (RR, 1.33; 95% CI, 1.03-1.71; P = 0.001, I2 = 55.1%). Only dyspnea improvement was significant compared to placebo even at the 300 microg indacaterol dose. Compared to placebo, a 12-week treatment of the long-acting beta-agonist, indacaterol might not have a significant effect on cough or phlegm in stable COPD.
